Skip to Content
MilliporeSigma

ZD1839 (Iressa) in non-small cell lung cancer.

The oncologist (2002-08-31)
Roy S Herbst, Merrill S Kies
ABSTRACT

Despite the advent of cisplatin-based combination chemotherapy for advanced non-small cell lung cancer (NSCLC), the prognosis for this patient population remains poor. Novel biologically targeted agents currently in development have the potential for greater efficacy against NSCLC, and possibly less toxicity than is associated with conventional cytotoxic chemotherapy. The epidermal growth factor receptor (EGFR) is recognized as a potentially useful target, and the small molecule, orally active EGFR-tyrosine kinase inhibitor ZD1839 (Iressa) is currently the furthest along in clinical development of the anti-EGFR agents. This review summarizes the currently available clinical data on the use of ZD1839 in the treatment of NSCLC.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Gefitinib, ≥98% (HPLC)